Akebia Therapeutics

About Akebia Therapeutics

Akebia Therapeutics is a biopharmaceutical company dedicated to transforming the treatment of kidney disease. Our mission is to develop innovative therapies that improve the lives of patients suffering from chronic kidney disease (CKD) and related conditions. We focus on discovering and commercialising novel therapeutics that target the underlying causes of kidney disease, rather than just managing symptoms.

Our flagship product, Vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anaemia associated with CKD. This groundbreaking therapy has shown promising results in clinical trials, demonstrating its potential to provide a new standard of care for patients.

At Akebia, we are committed to advancing scientific research and fostering collaborations with leading academic institutions and industry partners. Our team of experienced professionals is passionate about innovation and dedicated to bringing new treatments to market.

We believe in a patient-centric approach, ensuring that the needs and experiences of patients guide our research and development efforts. Our vision is to create a world where patients with kidney disease have access to effective and safe treatment options.

As we continue to grow, we remain focused on our core values of integrity, collaboration, and excellence. We strive to make a meaningful impact in the field of nephrology and improve health outcomes for patients globally.

Join us on our journey as we work towards a future where kidney disease is no longer a barrier to living a full and healthy life.